Feasibility and Potential Benefits of an Exercise Intervention in a Male With Down Syndrome Undergoing High-Dose Chemotherapy for Acute Lymphoblastic Leukemia: A Case Report.
Down syndrome
cancer
exercise
fatigue
leukemia
physical activity
Journal
Integrative cancer therapies
ISSN: 1552-695X
Titre abrégé: Integr Cancer Ther
Pays: United States
ID NLM: 101128834
Informations de publication
Date de publication:
Historique:
entrez:
24
2
2019
pubmed:
24
2
2019
medline:
18
12
2019
Statut:
ppublish
Résumé
In patients with hematological malignancies, exercise is studied as a supportive measure with potential benefits on therapy and disease-related side effects. However, clinical trials have not yet integrated people with Down syndrome (DS), although this disability is associated with an increased risk for hematological malignancies. Therefore, we examined safety and feasibility of a mixed-modality exercise intervention in a male with DS undergoing high-dose chemotherapy for acute lymphoblastic leukemia. Furthermore, physical capacity and fatigue were assessed. Exercise sessions took place 3 times/wk over a 5-week period. Adherence to the exercise program was 100%, and no serious adverse events occurred. In contrast to the training sessions, applied endurance testing was not feasible. Furthermore, maintenance of fatigue level was observed. In conclusion, cancer patients with DS suffering from leukemia should not be excluded from physical activity or exercise programs.
Identifiants
pubmed: 30795696
doi: 10.1177/1534735419832358
pmc: PMC6432678
doi:
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1534735419832358Références
Blood. 2014 Jan 2;123(1):70-7
pubmed: 24222333
Med Sci Sports Exerc. 1996 Mar;28(3):366-71
pubmed: 8776225
Contemp Clin Trials. 2016 Jul;49:1-5
pubmed: 27261170
Med Sci Sports Exerc. 2001 Oct;33(10):1655-60
pubmed: 11581548
Int J Cancer. 2001 Sep 1;93(5):741-4
pubmed: 11477589
Support Care Cancer. 2018 Oct;26(10):3337-3351
pubmed: 29936624
J Intellect Disabil Res. 2007 Mar;51(Pt 3):228-31
pubmed: 17300418
Support Care Cancer. 2019 Mar;27(3):1071-1079
pubmed: 30121789
Blood. 2010 Aug 19;116(7):1045-50
pubmed: 20442364
J Psychosom Res. 1995 Apr;39(3):315-25
pubmed: 7636775
J Pain Symptom Manage. 2008 May;35(5):524-34
pubmed: 18280104
Integr Cancer Ther. 2018 Jun;17(2):263-270
pubmed: 28627275
Support Care Cancer. 2003 Oct;11(10):623-8
pubmed: 12942360
Arch Intern Med. 2003 Mar 24;163(6):705-11
pubmed: 12639204
J Autism Dev Disord. 2016 Jun;46(6):2148-2159
pubmed: 26983920
Med Sci Sports Exerc. 2010 Jul;42(7):1409-26
pubmed: 20559064
Ther Clin Risk Manag. 2010 Dec 08;6:601-10
pubmed: 21206759
Arch Phys Med Rehabil. 2005 Oct;86(10):2051-8
pubmed: 16213253
Integr Cancer Ther. 2009 Jun;8(2):130-8
pubmed: 19679621
PLoS One. 2016 Jul 27;11(7):e0159966
pubmed: 27463234
Lancet. 2000 Jan 15;355(9199):165-9
pubmed: 10675114
Internist (Berl). 2012 Jun;53(6):688-97
pubmed: 22584271
Med Sci Sports Exerc. 2015 Feb;47(2):250-6
pubmed: 24983334
Cochrane Database Syst Rev. 2014 Nov 11;(11):CD009075
pubmed: 25386666
Int J Hematol. 2009 Sep;90(2):199-204
pubmed: 19629631
Med Sci Sports Exerc. 1993 Feb;25(2):270-4
pubmed: 8450732
J Cancer Surviv. 2010 Jun;4(2):87-100
pubmed: 20052559
Biol Res Nurs. 2016 Jul;18(4):432-8
pubmed: 26933148
Res Dev Disabil. 2017 Mar;62:81-103
pubmed: 28119223
Curr Sports Med Rep. 2006 Dec;5(6):315-8
pubmed: 17067499